About: Ulotaront

Property	Value
dbo:abstract	Ulotaront (INN; developmental codes SEP-363856, SEP-856) is an investigational antipsychotic that is undergoing clinical trials for the treatment of schizophrenia and Parkinson's disease psychosis. The medication was discovered in collaboration between PsychoGenics Inc. and Sunovion Pharmaceuticals using PsychoGenics' behavior and AI-based phenotypic drug discovery platform, SmartCube. Ulotaront is in Phase III of clinical development. Research has shown that ulotaront results in a greater reduction from baseline in the PANSS total score than placebo. Treatment with ulotaront, as compared with placebo, was also associated with an improvement in sleep quality. Ulotaront was awarded a Breakthrough Therapy designation due to its increased efficacy and greatly reduced side effects compared to current treatments. (en) SEP-363856 eller SEP-856, är en antipsykotika som tillhandahålls av Sunovion. SEP-856 befinner sig på utredningstadiet än. (sv)
dbo:casNumber	1310426-33-5
dbo:fdaUniiCode	3K6270MG59
dbo:kegg	D12474
dbo:pubchem	89532783
dbo:thumbnail	wiki-commons:Special:FilePath/SEP-363856.svg?width=300
dbo:wikiPageExternalLink	https://adisinsight.springer.com/drugs/800036955
dbo:wikiPageID	61101068 (xsd:integer)
dbo:wikiPageLength	10842 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID	1122158164 (xsd:integer)
dbo:wikiPageWikiLink	dbr:Psychosis dbr:Schizophrenia dbr:Trace_amine-associated_receptor_1 dbr:Dopamine_receptor dbr:List_of_investigational_antipsychotics dbc:Amines dbc:Experimental_drugs dbr:Brain dbr:TAAR1_agonist dbr:Antipsychotic dbr:Lurasidone dbr:Clinical_trial dbr:Receptor_antagonist dbr:Positive_and_Negative_Syndrome_Scale dbr:Trace_amine-associated_receptor dbc:5-HT1A_agonists dbr:Agonist dbr:Akathisia dbr:5-HT1A_receptor dbc:Antipsychotics dbr:Food_and_Drug_Administration dbr:Breakthrough_therapy dbr:Parkinson's_disease dbc:TAAR1_agonists dbc:Thiophenes dbr:Dyspepsia dbr:Adverse_effect dbr:Dopamine dbr:Placebo dbr:Pharmacokinetic dbr:D2_receptor dbr:Raul_Gainetdinov dbr:Serotonin dbr:Mechanism_of_action dbr:Sleep dbr:Movement_disorder dbr:Sunovion dbr:Ralmitaront
dbp:c	9 (xsd:integer)
dbp:casNumber	1310426 (xsd:integer)
dbp:chemspiderid	61321168 (xsd:integer)
dbp:h	13 (xsd:integer)
dbp:iupacName	1 (xsd:integer)
dbp:kegg	D12474 (en)
dbp:n	1 (xsd:integer)
dbp:o	1 (xsd:integer)
dbp:pubchem	89532783 (xsd:integer)
dbp:s	1 (xsd:integer)
dbp:smiles	CNC[C@H]1C2=CC=CS2 (en)
dbp:stdinchi	1 (xsd:integer)
dbp:stdinchikey	ABDDQTDRAHXHOC-QMMMGPOBSA-N (en)
dbp:synonyms	SEP-363856; SEP-856 (en)
dbp:unii	3 (xsd:integer)
dbp:width	150 (xsd:integer)
dbp:wikiPageUsesTemplate	dbt:Drugbox dbt:Reflist dbt:Short_description dbt:Abbrlink dbt:TAAR_ligands
dcterms:subject	dbc:Amines dbc:Experimental_drugs dbc:5-HT1A_agonists dbc:Antipsychotics dbc:TAAR1_agonists dbc:Thiophenes
rdf:type	owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:Drug
rdfs:comment	SEP-363856 eller SEP-856, är en antipsykotika som tillhandahålls av Sunovion. SEP-856 befinner sig på utredningstadiet än. (sv) Ulotaront (INN; developmental codes SEP-363856, SEP-856) is an investigational antipsychotic that is undergoing clinical trials for the treatment of schizophrenia and Parkinson's disease psychosis. The medication was discovered in collaboration between PsychoGenics Inc. and Sunovion Pharmaceuticals using PsychoGenics' behavior and AI-based phenotypic drug discovery platform, SmartCube. Ulotaront is in Phase III of clinical development. (en)
rdfs:label	Ulotaront (en) SEP-363856 (sv)
owl:sameAs	wikidata:Ulotaront dbpedia-sv:Ulotaront https://global.dbpedia.org/id/9T77f
prov:wasDerivedFrom	wikipedia-en:Ulotaront?oldid=1122158164&ns=0
foaf:depiction	wiki-commons:Special:FilePath/SEP-363856.svg
foaf:isPrimaryTopicOf	wikipedia-en:Ulotaront
is dbo:wikiPageRedirects of	dbr:SEP-363856 dbr:C9H13NOS dbr:SEP-856
is dbo:wikiPageWikiLink of	dbr:List_of_investigational_antipsychotics dbr:SEP-363856 dbr:TAAR1 dbr:C9H13NOS dbr:Sunovion dbr:SEP-856
is foaf:primaryTopic of	wikipedia-en:Ulotaront